Ferroportin/SLC40A1 Antibody Blocking Peptide
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-21502PEP
Key Product Details
Conjugate
Unconjugated
Applications
Antibody Competition
Product Specifications
Description
A SLC40A1 antibody blocking peptide.
Predicted Molecular Mass
62.5 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Application Notes
This peptide is useful as a blocking peptide for NBP1-21502. For further blocking peptide related protocol, click here.
Protein / Peptide Type
Antibody Blocking Peptide
Formulation, Preparation and Storage
NBP1-21502PEP
Formulation | Peptide dissovled in dH20. Contains no BSA. |
Preservative | No Preservative |
Concentration | 1.0 mg/ml |
Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Store at -80C. Avoid freeze-thaw cycles. |
Background: Ferroportin/SLC40A1
FPN1 regulation is dependent on the cell type and involves transcriptional, posttranscriptional, and posttranslational mechanisms including hepcidin-mediated endocytosis and proteolysis. Hepcidin controls the concentration of FPN1 in the membrane, with hepcidin deficiency resulting in iron overload (high iron) and hepcidin excess leading to iron restriction and anemia (2). Ferroportin disease or hemochromatosis type 4 (HFE4) is associated with distinct FPN1 variants with either reduced FPN1 cell surface expression/iron export capacity or hepcidin resistance and iron overload (3, 4).
References
1. De Domenico I, Ward DM, Kaplan J. (2011) Hepcidin and ferroportin: the new players in iron metabolism. Semin Liver Dis. 31(3):272-9. PMID: 21901657
2. Drakesmith H, Nemeth E, Ganz T. (2015) Ironing out Ferroportin. Cell Metab. 22(5):777-87. PMID: 26437604
3. Pietrangelo A. (2017) Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica. 102(12):1972-1984. PMID: 29101207
4. Vlasveld LT, Janssen R, Bardou-Jacquet E, Venselaar H, Hamdi-Roze H, Drakesmith H, Swinkels DW. (2019) Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features. Pharmaceuticals (Basel). 12(3). pii: E132. PMID: 31505869
Long Name
Solute Carrier Family 40 Member 1
Alternate Names
FPN1, HFE4, IREG1, MST079, MTP1, SLC11A3, SLC40A1
Gene Symbol
SLC40A1
Additional Ferroportin/SLC40A1 Products
Product Documents for Ferroportin/SLC40A1 Antibody Blocking Peptide
Product Specific Notices for Ferroportin/SLC40A1 Antibody Blocking Peptide
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...